Global HIV News
Treatment 08/05/2012
Frequent virologic monitoring limits NRTI and NNRTI resistance
Ongoing virologic monitoring, along with strict application of criteria for regimen switches, was associated with low rates of resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors, which in turn preserved second-line treatment options.
Hepatitis 08/05/2012
Aethlon reports undetectable HCV in genotype 1, genotype 3, and genotype 5 patients treated with Hemopurifier® therapy
The presence of HCV is currently undetectable in all infected patients that have been treated with the Aethlon Hemopurifier® in combination with peginterferon+ribavirin drug therapy and monitored for at least ninety days.
Treatment 08/05/2012
New BHIVA guidelines: HIV positive adults and HIV & pregnancy
BHIVA will produce implementation and audit tools to be used alongside these guidelines.
Access to treatment 08/05/2012
German ministry advises developing countries not to sign ACTA
Negative effects on generic drug distribution and trade is a huge concern.
Treatment 08/05/2012
Clinigen gains US FDA approval for Foscavir in HIV/AIDS‐related cytomegalovirus infections and herpes
Foscavir (foscarnet sodium) is licensed to treat cytomegalovirus (CMV) retinitis in HIV patients and acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immune-compromised patients.
Prevention 08/05/2012
Study confirms early elevated HIV infection risk in some Step study participants who received vaccine; risk decreased over time
After about 18 months, risk level decreased to that of volunteers who received a placebo.
Hepatitis 08/05/2012
New drugs require new terms for HCV virologic response
The development of drugs to treat hepatitis C virus is progressing rapidly, but the terminology to quantify virologic response is lagging.
Hepatitis 08/05/2012
Co-infection with hepatitis C increases mortality risk by 50% for patients with AIDS
A fifth of these deaths are attributable to liver-related causes, five times the rate seen in people with AIDS who are not co-infected.
World Policy 05/05/2012
Fund fighting killer diseases cuts jobs, to focus on 20 countries
The Global Fund is cutting its workforce and tightening its focus on 20 countries hardest hit by AIDS, tuberculosis and malaria.
Pharma Industry 05/05/2012
U.S. to partner with Big Pharma for drug discovery
Eli Lilly, Pfizer, AstraZeneca offer 24 compounds; Idea is to repurpose failed drugs for new uses; NIH providing $20 million in research grants; Successful projects eligible for royalties.
Pharma Industry 05/05/2012
Pfizer says Lyrica fails in diabetes trial, halts HIV study
Pfizer said the trial in HIV patients wasn’t ended for safety reasons.
Treatment 05/05/2012
Unplanned treatment interruptions involve a greater risk of virological failure than missing occasional doses
Unstructured treatment interruptions – rather than missed doses of medication – involve a greater risk of a detectable viral load.
Hepatitis 05/05/2012
"World hepatitis treatment and vaccine market will reach $8.7bn in 2012" visiongain report predicts
Visiongain forecasts that oral antivirals will be the largest sector of the hepatitis treatment and vaccines market in 2022.
Hepatitis 04/05/2012
Liver transplants in HIV-HCV co-infection—results from a U.S. study
The study has yielded important information that could be used by transplant teams to improve the survival of HIV-HCV-infected people who need a liver transplant.
Epidemiology 04/05/2012
HIV/AIDS: New book tracks the epidemic to its origins
“Tinderbox: How the West sparked the AIDS epidemic and how the world can finally overcome it”
EMA & FDA 04/05/2012
FDA must be proactive about postapproval drug safety: IOM
FDA to make postmarketing research of drugs' risks and benefits a priority and to develop a centralized system for managing all information about drugs throughout their life cycles.
Access to treatment 04/05/2012
Abbott, Kaletra pricing and AIDS in Colombia
In the latest struggle between Abbott Laboratories and patient advocacy groups, an administrative judge in Colombia recently ruled that the drugmaker and the government health ministry improperly maintained the price of the Kaletra AIDS medication above the so-called reference price.
Tuberculosis & Malaria 03/05/2012
TB identified as a top priority in fighting the biggest killer diseases
Research released by the Copenhagen Consensus Center identifies TB as a key priority for infectious disease control in terms of cost effectiveness and disease burden.
World Policy 03/05/2012
Six-year study in Rwanda finds influx of HIV/AIDS funding does not undermine health care services for other diseases
Study addresses long-standing debate about funding imbalances for global diseases.
Basic Science 03/05/2012
Study using stem cell therapy shows promise in fight against HIV
Researchers are a step closer to launching human clinical trials involving the use of an innovative stem cell therapy to fight the virus that causes AIDS.
More...
